Allogene Therapeutics Inc (NASDAQ:ALLO) currently has a daily average trading volume of 3.41M but it saw 1687019 shares traded in last market. With a market cap of 258.10M USD, the company’s current market price of $1.18 came rising about 3.51 while comparing to the previous closing price of $1.14. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.78 and as low as $0.86.
Citizens JMP upgraded its recommendation for the stock as a “Mkt Outperform” from “Mkt Perform” on March 14, 2025 while assigning a price target of $5. Oppenheimer issued its recommendations for the stock as it resumed the price target for the stock in the range of between $13 and $11.
Over the week, ALLO’s stock price is moving 6.31% up while it is -23.38% when we observe its performance for the past one month. Year-to-date it is -44.60% down and over the past year, the stock is showing a downside performance of -53.17%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of -0.26 while estimate for next year EPS is -1.01. In next quarter, company is expected to be making quarterly sales of $1.67k as analysts are expecting the sales for current fiscal year at $5k and seeing the company making $16.36k in sales next year. Moreover, analysts are in estimates of $1.67k for current-quarter revenue.
Currently, Allogene Therapeutics Inc’s total number of outstanding shares is 218.60M with 17.21% of that held by the insiders while 81.20% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -54.07% and return on equity (ROE) at -59.60%. Stock’s beta reads 0.31. Stock has a price to book (P/B) ratio of 0.67. Its return on asset (ROA) is -46.11% on average.
